Cristina V. Navarrete
Research Subjects
Cristina V. Navarrete has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Francesc Enric Borràs
REMAR‐IVECAT Group, “Germans Trias i Pujol” Health Science Research Institute and Nephrology Department “Germans Trias i Pujol” University Hospital Badalona Spain
3 shared publications D. Turner
2 shared publications- John Girdlestone
Department of Anatomy, MRC Centre for Immune Regulation, The Medical School, University of Birmingham, B15 2TT, UK
2 shared publications Juliette Brown
From the Histocompatibility and Immunogenetics Research Group and the Department of Histocompatibility and Immunogenetics, Colindale Centre, NHSBT; and the Department of Immunology and Molecular Pathology, UCL, Gower Street, London, UK
2 shared publicationsLisa E. Creary
From the Histocompatibility & Immunogenetics Research Group and the Histocompatibility & Immunogenetics Department, NHSBT, London; the Departments of Immunology and Molecular Pathology, University College London, London, UK; and the Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge, UK
2 shared publicationsM. P. Reynard
Department of Histocompatability & Immunogenetics, National Blood Dervice, London, UK
2 shared publications
Latest Publications
- Open Access
- 1 October 2009
- Published by Wiley in British Journal of Haematology
- Vol. 147 (2) , 236-245
Cord blood banking: a historical perspective
Summary: Umbilical cord blood (UCB) contains stem and progenitor cells capable of restoring haematopoietic and immunological function in vivo. UCB is currently used as an alternative source of haematopoietic stem cells for transplantation in patients suffering from haematological malignancies, bone marrow failures and inherited metabolic disorders. In order to facilitate transplantation, large repositories of frozen cord blood units (CBUs) from altruistic donations have been established in many parts of the world and to date there are more than 300 000 units stored worldwide. These products have been banked under stringent quality conditions, in order to ensure their safety and efficacy.The development and evolution of the policies and procedures currently in use in cord blood banking have been largely influenced by the clinical results of cord blood transplantation. This review aims to provide a historical overview of the various developments in the field of cord blood banking from its inception, highlighting the relevant aspects in their collection, banking and release that are known to influence the clinical outcome of these transplants.
- 1 October 2009
- Published by Wiley in British Journal of Haematology
- Vol. 147 (2) , 236-245
Open AccessCord blood banking: a historical perspective
Summary: Umbilical cord blood (UCB) contains stem and progenitor cells capable of restoring haematopoietic and immunological function in vivo. UCB is currently used as an alternative source of haematopoietic stem cells for transplantation in patients suffering from haematological malignancies, bone marrow failures and inherited metabolic disorders. In order to facilitate transplantation, large repositories of frozen cord blood units (CBUs) from altruistic donations have been established in many parts of the world and to date there are more than 300 000 units stored worldwide. These products have been banked under stringent quality conditions, in order to ensure their safety and efficacy.The development and evolution of the policies and procedures currently in use in cord blood banking have been largely influenced by the clinical results of cord blood transplantation. This review aims to provide a historical overview of the various developments in the field of cord blood banking from its inception, highlighting the relevant aspects in their collection, banking and release that are known to influence the clinical outcome of these transplants.
- 1 May 2009
- Published by Wiley in Transfusion
- Vol. 49 (5) , 953-958
Human platelet antigen typing of neonatal alloimmune thrombocytopenia patients using whole genome amplified DNA and a 5′-nuclease assay
A serious constraint in the investigation of the human platelet antigen (HPA) status of potential neonatal alloimmune thrombocytopenia (NAIT) cases is the limited amount of DNA available from the neonates. Whole genome amplification (WGA) of these DNA samples could overcome this problem, but requires validation to ensure that it is sufficiently sensitive and accurate before its application in a clinical diagnostic setting. This study has validated the use of WGA DNA for HPA-1, -2, -3, -4, -5, and -15 genotyping with a panel of six controls and 13 previously HPA-typed samples from neonates together with parental DNA, using a 5'-nuclease (TaqMan) assay. WGA was performed using titrated amounts of genomic and WGA DNA template. HPA typing was performed on genomic and amplified DNA using a 5'-nuclease assay or polymerase chain reaction with sequence-specific primers (PCR-SSP). WGA DNA yields were in the suggested range of 400x to 800x, as assessed by spectrophotometry and gel analysis, and did not require further purification. HPA genotyping showed 100 percent concordance when using down to 5 ng of genomic or WGA template. This study demonstrates that WGA can be used for HPA typing using PCR-SSP or plate-based 5'-nuclease assays. The use of WGA for HPA typing in clinical samples from NAIT patients was validated with 100 percent concordance, and it is suggested that this technology can be used for other analyses where DNA amounts are limited.
- 1 May 2009
- Published by Wiley in Transfusion
- Vol. 49 (5) , 953-958
Human platelet antigen typing of neonatal alloimmune thrombocytopenia patients using whole genome amplified DNA and a 5′-nuclease assay
A serious constraint in the investigation of the human platelet antigen (HPA) status of potential neonatal alloimmune thrombocytopenia (NAIT) cases is the limited amount of DNA available from the neonates. Whole genome amplification (WGA) of these DNA samples could overcome this problem, but requires validation to ensure that it is sufficiently sensitive and accurate before its application in a clinical diagnostic setting. This study has validated the use of WGA DNA for HPA-1, -2, -3, -4, -5, and -15 genotyping with a panel of six controls and 13 previously HPA-typed samples from neonates together with parental DNA, using a 5'-nuclease (TaqMan) assay. WGA was performed using titrated amounts of genomic and WGA DNA template. HPA typing was performed on genomic and amplified DNA using a 5'-nuclease assay or polymerase chain reaction with sequence-specific primers (PCR-SSP). WGA DNA yields were in the suggested range of 400x to 800x, as assessed by spectrophotometry and gel analysis, and did not require further purification. HPA genotyping showed 100 percent concordance when using down to 5 ng of genomic or WGA template. This study demonstrates that WGA can be used for HPA typing using PCR-SSP or plate-based 5'-nuclease assays. The use of WGA for HPA typing in clinical samples from NAIT patients was validated with 100 percent concordance, and it is suggested that this technology can be used for other analyses where DNA amounts are limited.
- Open Access
- 23 December 2008
- Published by Wiley in Transfusion
- Vol. 49 (1) , 57-63
Molecular typing of HLA genes using whole genome amplified DNA
The outcome of clinical transplantation and a number of disease susceptibilities show very strong associations with genetic variants within the major histocompatibility complex, particularly in the human leukocyte antigen (HLA) genes. A problem with many association studies is the lack of sufficient DNA to perform multiple genetic analyses, particularly with transplantation outcomes where donor and recipient DNA are often in short supply. This study assesses whether a multiple-strand displacement whole genome amplification (WGA) method could generate sufficient template of high quality to perform unbiased amplification for analysis of the HLA-A, -B, -C, -DRB1, and -DQB1 genes. A panel of DNA samples from various biological sources was subjected to WGA reaction using Phi29 DNA polymerase. The HLA genotypes were subsequently determined using standard polymerase chain reaction (PCR)-based methods including sequence-specific oligonucleotide probes (PCR-SSOP, Luminex, Luminex Corp.) and sequence-based typing (PCR-SBT). WGA products and original DNA samples were used to determine the sensitivity of the Luminex assay; in addition, reamplified WGA products were also genotyped. The WGA templates, as well as serially amplified DNA for two successive rounds, yielded HLA genotypes fully concordant with those determined for the original DNA samples. WGA products and original DNA gave reproducible HLA-DQB1 genotypes with 100 to 10 ng of template. Purification of the WGA products was required for successful PCR-SBT, but not for the PCR-SSOP method. Our study suggests that WGA can be a reliable method for generating unlimited DNA for medium- or high-resolution HLA typing using the techniques described above.
- 23 December 2008
- Published by Wiley in Transfusion
- Vol. 49 (1) , 57-63
Open AccessMolecular typing of HLA genes using whole genome amplified DNA
The outcome of clinical transplantation and a number of disease susceptibilities show very strong associations with genetic variants within the major histocompatibility complex, particularly in the human leukocyte antigen (HLA) genes. A problem with many association studies is the lack of sufficient DNA to perform multiple genetic analyses, particularly with transplantation outcomes where donor and recipient DNA are often in short supply. This study assesses whether a multiple-strand displacement whole genome amplification (WGA) method could generate sufficient template of high quality to perform unbiased amplification for analysis of the HLA-A, -B, -C, -DRB1, and -DQB1 genes. A panel of DNA samples from various biological sources was subjected to WGA reaction using Phi29 DNA polymerase. The HLA genotypes were subsequently determined using standard polymerase chain reaction (PCR)-based methods including sequence-specific oligonucleotide probes (PCR-SSOP, Luminex, Luminex Corp.) and sequence-based typing (PCR-SBT). WGA products and original DNA samples were used to determine the sensitivity of the Luminex assay; in addition, reamplified WGA products were also genotyped. The WGA templates, as well as serially amplified DNA for two successive rounds, yielded HLA genotypes fully concordant with those determined for the original DNA samples. WGA products and original DNA gave reproducible HLA-DQB1 genotypes with 100 to 10 ng of template. Purification of the WGA products was required for successful PCR-SBT, but not for the PCR-SSOP method. Our study suggests that WGA can be a reliable method for generating unlimited DNA for medium- or high-resolution HLA typing using the techniques described above.
- 1 April 2006
- Published by Wiley in Vox Sanguinis
- Vol. 90 (3) , 205
The immunogenicity of white cell fragments in platelet concentrates
- 1 April 2006
- Published by Wiley in Vox Sanguinis
- Vol. 90 (3) , 205
The immunogenicity of white cell fragments in platelet concentrates
- 1 June 2004
- Published by Wiley in Vox Sanguinis
- Vol. 87 (s1) , 39-42
ES03.03 Immunity and transplantation
- 1 June 2004
- Published by Wiley in Vox Sanguinis
- Vol. 87 (s1) , 39-42
ES03.03 Immunity and transplantation
- Open Access
- 1 April 2004
- Published by Wiley in British Journal of Haematology
- Vol. 125 (3) , 358-365
The London Cord Blood Bank: analysis of banking and transplantation outcome
Summary: Cord blood units (n = 5500) stored at the London Cord Blood Bank, including 59 units transplanted into a high risk and heterogeneous group of patients, were analysed. Transplant outcome data was available for 44 patients with a median clinical follow‐up of 14 months (range 3–44 months). Over 40% of the collected units were of ethnic minority origin with a median volume of 79 ml (range 40–240 ml) and a median total nucleated cell (TNC) count of 11·9 × 109/l (range 10·0–24·8 × 109/l). The average patient's weight was 28 kg (range 5–80 kg) and the median age was 8 years (range 0·7–40 years). The median number of nucleated cells infused was 4 × 107/kg (range 1·10–16 × 107/kg). Neutrophil engraftment of 0·5 × 109/l was observed in 33 (74±%) patients with an average time of 28 days (range 11–60). The Kaplan‐Meier estimate of acute graft‐versus‐host disease (grade II >) at day 100 was 37 ± 7% and in 27 (62%) patients, it was grade I or absent. The overall survival and disease‐free survival at 2 years was 49 ± 8% and 41 ± 8%, respectively. Two years after transplantation the survival rate was 69% and 54% for patients receiving a 6/6 or 5/6 HLA matched units, respectively. Infection was the main cause of transplanted related mortality in these patients.
- 1 April 2004
- Published by Wiley in British Journal of Haematology
- Vol. 125 (3) , 358-365
Open AccessThe London Cord Blood Bank: analysis of banking and transplantation outcome
Summary: Cord blood units (n = 5500) stored at the London Cord Blood Bank, including 59 units transplanted into a high risk and heterogeneous group of patients, were analysed. Transplant outcome data was available for 44 patients with a median clinical follow‐up of 14 months (range 3–44 months). Over 40% of the collected units were of ethnic minority origin with a median volume of 79 ml (range 40–240 ml) and a median total nucleated cell (TNC) count of 11·9 × 109/l (range 10·0–24·8 × 109/l). The average patient's weight was 28 kg (range 5–80 kg) and the median age was 8 years (range 0·7–40 years). The median number of nucleated cells infused was 4 × 107/kg (range 1·10–16 × 107/kg). Neutrophil engraftment of 0·5 × 109/l was observed in 33 (74±%) patients with an average time of 28 days (range 11–60). The Kaplan‐Meier estimate of acute graft‐versus‐host disease (grade II >) at day 100 was 37 ± 7% and in 27 (62%) patients, it was grade I or absent. The overall survival and disease‐free survival at 2 years was 49 ± 8% and 41 ± 8%, respectively. Two years after transplantation the survival rate was 69% and 54% for patients receiving a 6/6 or 5/6 HLA matched units, respectively. Infection was the main cause of transplanted related mortality in these patients.
- 6 January 2004
- Published by Wiley in Tissue Antigens
- Vol. 63 (2) , 149-157
Differential up‐regulation of HLA‐DM, invariant chain, and CD83 on myeloid and plasmacytoid dendritic cells from peripheral blood
Abstract: Two main dendritic cell (DC) subsets have been described in peripheral blood, the myeloid subset or DC1 that is characterized by the presence of CD11c and the plasmacytoid subset or DC2 negative for this marker. The two subsets may perform different functions and have been defined as immunogenic (the myeloid subset) or tolerogenic (the plasmacytoid subset). The expression of human leukocyte antigen (HLA)‐DM molecules, which act as peptide editors in the antigen presentation process, was studied in freshly isolated plasmacytoid and myeloid DCs from peripheral blood. The expression of the invariant chain (Ii), the major histocompatibility complex class II (MHC‐II) : class II‐associated Ii peptide (CLIP) complex, and CD83 was also investigated. The results showed that intracellular expression of HLA‐DM and the Ii was significantly higher in the plasmacytoid than in the myeloid DC subset. In contrast, a higher fraction of cell expressing MHC‐II : CLIP complex was found in the myeloid than in the plasmacytoid DC subpopulation. CD83 was not detected in any of these two subsets. Following culture of these cells with interleukin‐3 (IL‐3), tumor necrosis factor‐α (TNFα) and/or heat shock protein‐70 (HSP‐70), the expression of intracellular HLA‐DM was up‐regulated in the myeloid DCs to levels similar to those found in the plasmacytoid DCs, whilst the Ii was down‐regulated in the plasmacytoid subset to similar levels to those expressed in the myeloid DCs. In addition, CD83 was up‐regulated in the myeloid (CD11c+) but not in the plasmacytoid (CD11c–) DCs. The expression pattern of these antigen‐processing molecules could be related to the immaturity and function attributed to these DC subsets.
- 6 January 2004
- Published by Wiley in Tissue Antigens
- Vol. 63 (2) , 149-157
Differential up‐regulation of HLA‐DM, invariant chain, and CD83 on myeloid and plasmacytoid dendritic cells from peripheral blood
Abstract: Two main dendritic cell (DC) subsets have been described in peripheral blood, the myeloid subset or DC1 that is characterized by the presence of CD11c and the plasmacytoid subset or DC2 negative for this marker. The two subsets may perform different functions and have been defined as immunogenic (the myeloid subset) or tolerogenic (the plasmacytoid subset). The expression of human leukocyte antigen (HLA)‐DM molecules, which act as peptide editors in the antigen presentation process, was studied in freshly isolated plasmacytoid and myeloid DCs from peripheral blood. The expression of the invariant chain (Ii), the major histocompatibility complex class II (MHC‐II) : class II‐associated Ii peptide (CLIP) complex, and CD83 was also investigated. The results showed that intracellular expression of HLA‐DM and the Ii was significantly higher in the plasmacytoid than in the myeloid DC subset. In contrast, a higher fraction of cell expressing MHC‐II : CLIP complex was found in the myeloid than in the plasmacytoid DC subpopulation. CD83 was not detected in any of these two subsets. Following culture of these cells with interleukin‐3 (IL‐3), tumor necrosis factor‐α (TNFα) and/or heat shock protein‐70 (HSP‐70), the expression of intracellular HLA‐DM was up‐regulated in the myeloid DCs to levels similar to those found in the plasmacytoid DCs, whilst the Ii was down‐regulated in the plasmacytoid subset to similar levels to those expressed in the myeloid DCs. In addition, CD83 was up‐regulated in the myeloid (CD11c+) but not in the plasmacytoid (CD11c–) DCs. The expression pattern of these antigen‐processing molecules could be related to the immaturity and function attributed to these DC subsets.
- 19 March 2003
- Published by Wiley in European Journal of Immunogenetics
- Vol. 30 (2) , 149-151
Allele frequencies for an interferon‐γ microsatellite in a population of Brazilian leprosy patients
Summary: A group of Brazilian leprosy patients and controls were genotyped for a CA‐repeat microsatellite polymorphism within the interferon (IFN)‐γ gene. A significantly higher frequency of alleles 5–7 was observed in this patient population, indicating that IFN‐γ gene polymorphism may contribute to the course of leprosy post‐infection.
- 19 March 2003
- Published by Wiley in European Journal of Immunogenetics
- Vol. 30 (2) , 149-151
Allele frequencies for an interferon‐γ microsatellite in a population of Brazilian leprosy patients
Summary: A group of Brazilian leprosy patients and controls were genotyped for a CA‐repeat microsatellite polymorphism within the interferon (IFN)‐γ gene. A significantly higher frequency of alleles 5–7 was observed in this patient population, indicating that IFN‐γ gene polymorphism may contribute to the course of leprosy post‐infection.
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (6) , 923-928
Cord Blood Dendritic Cells: Subsets, Functional Characteristics and In Vitro Generation
Dendritic cells (DCs) form a heterogeneous population of cells capable of stimulating naive T cells and initiating primary immune responses. This well-known function of DCs has offered the possibility of developing clinical protocols for their use in immunotherapy to tumours. DCs may also play a critical role in the induction of peripheral immunological tolerance, which could have important implications in the treatment of autoimmunity or in the outcome of clinical transplantation. Recent reports have indicated that cord blood transplantation is associated with a reduced incidence of graft versus host disease. Thus studies on the identification and characterisation of DCs present in, or derived from cord blood will help to understand their role, not only in neonatal immunity, but also in the outcome of cord blood transplantation.
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (6) , 923-928
Cord Blood Dendritic Cells: Subsets, Functional Characteristics and In Vitro Generation
Dendritic cells (DCs) form a heterogeneous population of cells capable of stimulating naive T cells and initiating primary immune responses. This well-known function of DCs has offered the possibility of developing clinical protocols for their use in immunotherapy to tumours. DCs may also play a critical role in the induction of peripheral immunological tolerance, which could have important implications in the treatment of autoimmunity or in the outcome of clinical transplantation. Recent reports have indicated that cord blood transplantation is associated with a reduced incidence of graft versus host disease. Thus studies on the identification and characterisation of DCs present in, or derived from cord blood will help to understand their role, not only in neonatal immunity, but also in the outcome of cord blood transplantation.
- 1 January 2002
- Published by Taylor & Francis in Hematology
- Vol. 7 (2) , 119-121
Major Histocompatibility Complex Susceptibility Genes and Immune Thrombocytopenic Purpura in Caucasian Adults
Immune thrombocytopenic purpura (ITP) is a heterogeneous disorder with wide variability in response rates to treatments including corticosteroids, splenectomy and intravenous immune globulins. The nature of the underlying predisposing causes for this autoimmune disorder are not known. We have HLA typed 71 adult Caucasian patients with chronic primary ITP, and compared the data with 750 control samples. In this association study, we were not able to identify a significant immunogenetic susceptibility factor for ITP with HLA class I and class II alleles. However, it appeared that there might be an association between HLA-A2 and ITP, particularly in female patients, who are the predominantly affected group; and HLA-A2 was also present at increased frequency in patients with chronic ITP progressing to splenectomy. These findings are reviewed in the context of other similar reported HLA studies in ITP. Further studies based on larger groups of patients will be necessary to identify genetic susceptibility factors for this disease.
- 1 January 2002
- Published by Taylor & Francis in Hematology
- Vol. 7 (2) , 119-121
Major Histocompatibility Complex Susceptibility Genes and Immune Thrombocytopenic Purpura in Caucasian Adults
Immune thrombocytopenic purpura (ITP) is a heterogeneous disorder with wide variability in response rates to treatments including corticosteroids, splenectomy and intravenous immune globulins. The nature of the underlying predisposing causes for this autoimmune disorder are not known. We have HLA typed 71 adult Caucasian patients with chronic primary ITP, and compared the data with 750 control samples. In this association study, we were not able to identify a significant immunogenetic susceptibility factor for ITP with HLA class I and class II alleles. However, it appeared that there might be an association between HLA-A2 and ITP, particularly in female patients, who are the predominantly affected group; and HLA-A2 was also present at increased frequency in patients with chronic ITP progressing to splenectomy. These findings are reviewed in the context of other similar reported HLA studies in ITP. Further studies based on larger groups of patients will be necessary to identify genetic susceptibility factors for this disease.